- Home
- KMDA vs ATXS Comparison
KMDA vs ATXS Comparison
Compare KMDA & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- ATXS
- Stock Information
- Founded
- KMDA 1990
- ATXS 2008
- Country
- KMDA Israel
- ATXS United States
- Employees
- KMDA N/A
- ATXS N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- ATXS Health Care
- Exchange
- KMDA Nasdaq
- ATXS Nasdaq
- Market Cap
- KMDA 442.1M
- ATXS 401.2M
- IPO Year
- KMDA N/A
- ATXS 2015
- Fundamental
- Price
- KMDA $7.46
- ATXS $6.81
- Analyst Decision
- KMDA Strong Buy
- ATXS Strong Buy
- Analyst Count
- KMDA 2
- ATXS 6
- Target Price
- KMDA $14.50
- ATXS $25.67
- AVG Volume (30 Days)
- KMDA 346.0K
- ATXS 244.9K
- Earning Date
- KMDA 03-05-2025
- ATXS 03-03-2025
- Dividend Yield
- KMDA N/A
- ATXS N/A
- EPS Growth
- KMDA 124.29
- ATXS N/A
- EPS
- KMDA 0.27
- ATXS N/A
- Revenue
- KMDA $158,380,000.00
- ATXS N/A
- Revenue This Year
- KMDA $15.37
- ATXS N/A
- Revenue Next Year
- KMDA $8.58
- ATXS N/A
- P/E Ratio
- KMDA $28.13
- ATXS N/A
- Revenue Growth
- KMDA 4.52
- ATXS N/A
- 52 Week Low
- KMDA $4.74
- ATXS $6.64
- 52 Week High
- KMDA $9.15
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- KMDA 52.89
- ATXS 31.94
- Support Level
- KMDA $7.51
- ATXS $6.77
- Resistance Level
- KMDA $8.35
- ATXS $7.30
- Average True Range (ATR)
- KMDA 0.41
- ATXS 0.30
- MACD
- KMDA -0.02
- ATXS 0.02
- Stochastic Oscillator
- KMDA 33.20
- ATXS 14.66
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.